Current Report Filing (8-k)
June 01 2020 - 8:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 1, 2020
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-31812
|
58-2301143
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
210 Main Street West
Baudette, Minnesota
|
|
56623
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (218) 634-3500
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class:
|
|
Trading Symbol(s):
|
Name of each exchange on which registered:
|
Common Stock
|
|
ANIP
|
Nasdaq Stock Market
|
(Former name or former address, if changed
since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2)
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events
On June 1, 2020, ANI Pharmaceuticals, Inc.
(the “Company”) issued a press release providing an update on the timeline for resubmission of its supplemental New
Drug Application (“sNDA”) for Cortrophin® Gel. As previously disclosed, the Company received a Refusal to File
(“RTF”) letter regarding its sNDA for Cortrophin® Gel from the U.S. Food and Drug Administration (“FDA”)
in April 2020. The Company has decided to concentrate its efforts on a resubmission of its sNDA, which will address the items identified
in the RTF letter, and will not request a Type A meeting with the FDA at this time. The Company has retained a prominent regulatory
consulting firm to support its plan to conduct a comprehensive review of the sNDA before resubmission. The Company currently expects
to resubmit its sNDA for Cortrophin® Gel upon completion of the review process. A copy of the Company’s press release
is attached hereto as Exhibit 99.1.
Forward-Looking Statements
To the extent any statements made in this
report deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the Company’s beliefs regarding
its review and observations relating to its initial Cortophin® Gel sNDA filing, the Company’s beliefs concerning its
ability to satisfactorily respond to the matters raised in the FDA’s RTF letter in a resubmission of the filing, the Company’s
beliefs concerning the information and activities required to resubmit to the FDA the Cortophin® Gel sNDA filing, the timing
of resubmission of the Company’s sNDA to the FDA and the timing and outcome of the FDA’s review of any resubmitted
sNDA relating to the Cortophin® Gel product.
These statements are only predictions and
involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results to be materially
different from these forward-looking statements. There can be no assurances that the results of the additional review and
refiling plan will be successful, that the Company will be able to successfully develop the additional information that may be
required for resubmission of the sNDA, or concerning the timing of completion of development of any additional information for
resubmission of the sNDA. In addition, there can be no assurance that the FDA will conclude that any sNDA that the Company
resubmits will satisfactorily respond to the matters raised in the FDA’s RTF letter, or concerning the timing of any resubmission
by the Company of the sNDA, that the FDA will approve our sNDA relating to our Cortophin® Gel product or concerning
the timing of any future action by the FDA on our sNDA, regarding the commercialization options that the Company will
pursue if our sNDA is approved, or that the product will be able to compete successfully in the market if approved and launched.
Certain of these risks are described more
fully in the Company’s filings with the Securities and Exchange Commission, including its most recent annual report on Form
10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this report speak
only as of the date of this report and are based on the Company’s current beliefs, assumptions, and expectations. The
Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ANI PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Stephen P. Carey
|
|
|
|
|
Stephen P. Carey
|
|
|
|
|
Vice President Finance, and Chief Financial Officer
|
|
Dated: June 1, 2020
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Apr 2023 to Apr 2024